Helicon CEO Peter Abrahamson On Exploiting Niche Markets In China: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Perth, Australia-based Helicon was established in 2003 to identify and exploit niche market opportunities in the specialty pharmaceutical and health care markets of China and North Asia. The company has licensed exclusive marketing rights for four products: Volplex, Collatamp, MedWrap with Microban and Recell. PharmAsia News' Australian bureau recently sat down with Helicon CEO Peter Abrahamson to discuss the company's business strategy in China.
You may also be interested in...
Stranded Pigs Rescued By NZ Biotech, Helicon SFDA Approval For Skin Regeneration Device, Arana Ramps Up R&D - Australia/New Zealand Roundup
Stranded New Zealand Pig Herd Could Offer Better Treatments For Diabetes
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).